CSIMarket Company Name, Ticker, Competitors, else..
 

Fulcrum Therapeutics Inc   (NASDAQ: FULC)

Fulcrum Therapeutics Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

FULC Sales vs. its Competitors Q1 2026


Comparing the current results to its competitors, Fulcrum Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.1 %, recorded in the same quarter.

• List of FULC Competitors





Revenue Growth Comparisons




Net Income Comparison

Fulcrum Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 28.34 %

<<  FULC Stock Performance Comparisons


Fulcrum Therapeutics Inc 's Comment on Competition and Industry Peers


The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapidly advancing technologies and intense competition. Its competitors include major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. The company is developing product candidates for sickle cell disease (SCD), focusing on small molecule oral therapies designed to increase HbF levels. The competitive landscape includes existing therapies and new product candidates from other developers. The company also faces risks related to patent protection and intellectual property rights that may impact its competitive position.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Fulcrum Therapeutics Inc




Transcode Therapeutics Inc
Share Performance



-84.27%
One Year
Transcode Therapeutics Inc
Profile

Transcode Therapeutics Inc's business model revolves around developing innovative RNA-based therapies to treat a wide range of diseases. By leveraging their expertise in mRNA biology and proprietary drug delivery technology, they aim to create transformative treatments with optimized safety and efficacy profiles.

More about Transcode Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 16.110 mill. $ - mill. $ -42.834 mill.


Cell Source Inc
Share Performance



-10.00%
This Year
Cell Source Inc
Profile

Cell Source Inc is a biotechnology company that specializes in the development and commercialization of innovative treatments for diseases. Their business model focuses on leveraging advanced cell therapy technologies to create personalized and regenerative therapies for patients. By partnering with research institutions and healthcare organizations, Cell Source aims to bring their cutting-edge solutions to the market, ultimately improving health outcomes and patient quality of life.

More about Cell Source Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 20.267 mill. $ - mill. $ -4.719 mill.


Forte Biosciences Inc
Share Performance



+226.09%
This Year
Forte Biosciences Inc
Profile

Forte Biosciences Inc is a biotechnology company focused on developing and commercializing innovative solutions for the treatment of dermatological diseases. Their business model centers around researching, developing, and bringing to market products that address unmet needs in the field of skin health through their proprietary technology platform.

More about Forte Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,634.427 mill. $ - mill. $ -87.937 mill.


Zyversa Therapeutics Inc
Share Performance



-26.67%
This Year
Zyversa Therapeutics Inc
Profile

Zyversa Therapeutics Inc's business model revolves around developing innovative therapies and treatments for various medical conditions.

More about Zyversa Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.801 mill. $ - mill. $ -24.489 mill.


Nanoviricides inc
Share Performance



-30.34%
One Year
Nanoviricides inc
Profile

Nanoviricides Inc. is a pharmaceutical company that operates on a business model based on the development and commercialization of nanomedicines.

More about Nanoviricides inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 21.826 mill. $ - mill. $ -8.091 mill.

61 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Fulcrum Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Fulcrum Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.